Sarcosine as an Add-On Treatment for Schizophrenia

Sarcosine, a naturally occurring amino acid also known as N-methylglycine, has shown modest but real benefits as an add-on treatment for schizophrenia in several clinical trials. It works by boosting the activity of NMDA receptors in the brain, which are thought to be underperforming in people with schizophrenia. The evidence is strongest for reducing negative symptoms like social withdrawal and flat emotions, and the effect sizes are small to moderate. There is a significant catch, though: sarcosine appears to do nothing when added to clozapine, the antipsychotic typically reserved for treatment-resistant cases.

How Sarcosine Works in the Brain

To understand why researchers are interested in sarcosine for schizophrenia, you need a quick detour through how certain brain receptors function. NMDA receptors are a type of receptor that plays a major role in learning, memory, and overall brain signaling. These receptors need two things to activate: the neurotransmitter glutamate and a co-agonist, which is usually glycine or a related molecule called D-serine. The idea behind sarcosine is straightforward: if NMDA receptors in schizophrenia are not working well enough, you can try to boost their activity by increasing the amount of glycine available at the synapse.

Sarcosine does this by blocking the glycine transporter type 1 (GlyT-1), the protein responsible for vacuuming glycine out of the synapse after it’s been released. When GlyT-1 is inhibited, more glycine hangs around in the synaptic gap, making it easier for NMDA receptors to fire. Animal studies have confirmed that sarcosine can reverse some of the behavioral disruptions caused by drugs that block NMDA receptors, including deficits in sensorimotor gating and excessive movement, both considered rough analogs of psychotic symptoms.¹ Sarcosine also appears to act directly on NMDA receptors themselves, not just indirectly through glycine levels.²

It is worth noting that the broader theory underpinning this research, the NMDA receptor hypofunction hypothesis, is not without controversy. Some researchers have pointed out that the clinical trial record for NMDA-targeting treatments has been disappointing overall, and that the evidence does not cleanly support the idea that NMDA underactivity is central to schizophrenia’s biology.³ Sarcosine’s results, while positive in several trials, exist within this larger picture of mixed outcomes for glutamate-based strategies.

What the Clinical Trials Actually Show

The human evidence for sarcosine in schizophrenia comes from a handful of randomized, double-blind, placebo-controlled trials, mostly conducted in Taiwan and Poland. These are small studies, but their results have been fairly consistent in direction. The first published trial found that patients who took sarcosine on top of their regular antipsychotics showed significant improvements in positive symptoms (like hallucinations and delusions), negative symptoms (like emotional flatness and social withdrawal), cognitive function, and general psychiatric symptoms compared to placebo.⁴

A later trial comparing sarcosine, D-serine (another NMDA-enhancing compound), and placebo found that sarcosine outperformed both. Sarcosine-treated patients improved on total symptom scores, negative symptom scores, quality of life, and global functioning. D-serine, by contrast, did not significantly differ from placebo on any measure.⁵ This head-to-head comparison mattered because D-serine had been one of the most studied NMDA-enhancing agents, and sarcosine’s superiority suggested that blocking glycine reuptake might be more effective than directly supplying an NMDA co-agonist.

Another trial focused specifically on patients experiencing acute exacerbation of schizophrenia, testing sarcosine, D-serine, and placebo side by side. Sarcosine was superior to both placebo and D-serine in reducing negative symptoms specifically.⁶ Negative symptoms are a particularly important target because they respond poorly to conventional antipsychotics and are among the strongest predictors of long-term disability.

Effects on Thinking and Cognition

Cognitive problems in schizophrenia, including difficulty with memory, attention, and executive function, are some of the most debilitating aspects of the illness and are notoriously hard to treat. Sarcosine’s relationship with cognitive improvement is more complicated than its relationship with negative symptoms. One trial found that sarcosine alone did not significantly improve cognitive function, but when combined with sodium benzoate (another compound that enhances NMDA receptor signaling through a different mechanism), cognitive and global functioning improved even in patients whose clinical symptoms remained stable.⁷

That last finding is intriguing because it suggests the cognitive benefits might be separable from symptomatic improvement. In other words, NMDA-enhancing treatment could help someone think more clearly without necessarily changing their hallucinations or delusions. This would be clinically meaningful for the many patients whose psychotic symptoms are reasonably controlled by antipsychotics but who still struggle with the cognitive fog that limits their ability to work, maintain relationships, or live independently.

The Clozapine Problem

One of the most consistent findings across sarcosine research is that it does not appear to work when added to clozapine. This was first demonstrated in a dedicated trial where sarcosine was tested specifically in patients already taking clozapine, which is the antipsychotic typically reserved for people who haven’t responded to other medications. The results showed no improvement across any symptom domain.⁸

Two separate meta-analyses have confirmed this pattern. One found that sarcosine combined with first- and second-generation antipsychotics, except clozapine, had a positive effect.⁹ The other showed that sarcosine reduced symptom severity specifically in people with chronic schizophrenia who were not on clozapine, but not in those who were.¹⁰

The leading explanation is that clozapine itself already enhances NMDA neurotransmission through its own pharmacological profile, so adding sarcosine on top of it is redundant. If clozapine is already pushing NMDA signaling as far as it can usefully go, a glycine transporter inhibitor has nothing left to add. This is frustrating from a clinical standpoint, because the people on clozapine are precisely those with the most treatment-resistant illness and the greatest unmet need.

Dosing and Side Effects

Most clinical trials have used sarcosine at a dose of 2 grams per day, typically split into two doses. An open-label pharmacokinetic study tested both 2 g/day and 4 g/day in stabilized patients and found that sarcosine is absorbed quickly, reaching peak blood levels within about one and a half to two and a half hours, with a short half-life of around one hour.¹¹ That short half-life is part of why twice-daily dosing is standard in studies.

Across trials, sarcosine has generally been well tolerated. Side effects are typically mild and reported at rates similar to placebo. However, a case report detailed an interesting reaction in one patient taking 2 g/day: after initial improvement in activity, concentration, and mood during the first two weeks, the patient developed moderate inner tension, excessive activity, irritability, and a significant increase in sexual tension over the following two weeks. These symptoms were distressing enough that his dose was cut in half to 1 g/day, after which the unpleasant symptoms subsided and he described his overall mental state as better than before sarcosine or during the higher dose.¹²

This case raises the possibility that the commonly studied dose of 2 g/day may be too much for some individuals, and that a lower dose could provide the benefits without overstimulation. The authors speculated that sarcosine’s effects on NMDA receptors might interact with serotonin signaling at higher doses, creating a state resembling hypomania. It was a single case, so drawing broad conclusions would be premature, but it highlights that “well tolerated on average” does not mean side-effect-free for everyone.

Sarcosine Levels Are Already Altered in Schizophrenia

An interesting twist in the sarcosine story is that people with schizophrenia already appear to have abnormal sarcosine levels in their blood. A case-control study comparing amino acid profiles found that sarcosine (along with cysteine, GABA, and glutamine) was elevated in people with schizophrenia compared to healthy controls, even after adjusting for age, sex, and body mass.¹³ A more recent metabolomics study confirmed that sarcosine was among the neurotransmitters significantly upregulated in early-onset schizophrenia, and that sarcosine levels correlated positively with positive symptoms, negative symptoms, and general psychiatric symptom severity.¹⁴

This creates a seeming paradox: if sarcosine is already elevated in schizophrenia, why would giving more of it help? One possibility is that peripheral blood levels don’t reflect what’s happening at the synapse in the brain. Blood sarcosine might be high because it’s being produced elsewhere in the body or because the transporters that normally clear it are functioning differently in schizophrenia, while synaptic glycine levels in the brain remain too low for optimal NMDA receptor function. Another possibility is that the elevated blood sarcosine is a compensatory response to some underlying deficit, much like the body might overproduce a substance that isn’t getting where it needs to go. These biomarker studies are still in early stages and are more useful for understanding the metabolic landscape of schizophrenia than for guiding treatment decisions right now.

The Prostate Cancer Question

Anyone researching sarcosine supplements will eventually encounter warnings about prostate cancer, and this concern deserves a clear-eyed look. The connection comes from two directions. First, laboratory research has shown that sarcosine plays a role in prostate cancer metabolism: the enzyme that produces sarcosine is elevated in prostate tumors, while the enzymes that break it down are reduced, and manipulating these enzymes in cell lines affected the cancerous behavior of the cells.¹⁵

Second, a large prospective study using data from a major cancer screening trial found that men with higher blood levels of sarcosine had a modestly increased risk of prostate cancer overall. Specifically, those in the highest quarter of sarcosine levels had about a 30% higher risk compared to those in the lowest quarter. However, when the researchers looked at aggressive versus non-aggressive prostate cancer separately, the association was only present for non-aggressive disease and was absent for aggressive prostate cancer.¹⁶

What does this mean for someone considering sarcosine supplementation? The honest answer is that we don’t know whether taking sarcosine orally at the doses used in schizophrenia trials (2 g/day for weeks to months) meaningfully raises prostate cancer risk. The prospective study measured naturally circulating sarcosine levels, not levels resulting from supplementation, and the association it found was modest and limited to non-aggressive disease. The lab studies show sarcosine matters in prostate tumor biology, but metabolic conditions inside a tumor are very different from what happens when you take a supplement. None of the schizophrenia clinical trials have been large enough or long enough to assess cancer outcomes. For men, especially those with a family history of prostate cancer or other risk factors, this is a reasonable concern to raise with a doctor before starting sarcosine. For women and younger men with low baseline prostate cancer risk, the relevance is less clear.

Where Sarcosine Fits in the Treatment Landscape

Sarcosine is not an approved pharmaceutical for schizophrenia in any major regulatory jurisdiction. It is sold as a dietary supplement, which means it is not subject to the same manufacturing standards, dosing consistency, or quality controls as prescription medications. This creates a practical gap between the clinical trial evidence (where pure, pharmaceutical-grade sarcosine was used) and what a person can actually buy. The purity and actual sarcosine content of supplements can vary between brands and even between batches.

The clinical data, while encouraging in direction, is also limited in quantity. The total number of patients studied across all randomized trials of sarcosine for schizophrenia is in the low hundreds, and the trials have been short, mostly six to twelve weeks. No one has studied long-term outcomes, relapse prevention, or functional recovery over months or years. The meta-analyses that have pooled these trials describe the overall effect as small to moderate, and one of them calculated effect sizes that, while statistically significant, were not large enough to be considered transformative on their own.¹⁷

The lack of pharmaceutical industry interest is both a feature and a bug. Sarcosine is a simple, naturally occurring amino acid that cannot be patented, which means no company has the financial incentive to fund the large, expensive trials needed for regulatory approval. This is a common problem for repurposed or natural compounds: the evidence stays stuck at the “promising but inconclusive” stage because no one wants to pay for the definitive study. Researchers working on NMDA-enhancing strategies have continued to explore related approaches, including proprietary GlyT-1 inhibitors that could be patented, but none of these have made it to widespread clinical use for schizophrenia either.

Sarcosine Beyond the Brain

Sarcosine is not just a brain chemical. It is a normal intermediate in the body’s metabolism of glycine and methionine, two common amino acids. Your body produces it naturally, and it is present in foods like egg yolks, turkey, and legumes, though in small amounts compared to supplemental doses. In the body, sarcosine is produced by the enzyme glycine N-methyltransferase (GNMT) and broken down by sarcosine dehydrogenase (SARDH). The balance between these two enzymes determines how much sarcosine is circulating at any given time.

The prostate cancer research described earlier highlighted how this balance shifts in tumor tissue, but outside of cancer biology, sarcosine metabolism is simply part of normal one-carbon metabolism, the same set of pathways involved in DNA methylation and folate cycling. There is no evidence that taking sarcosine at the doses studied disrupts these pathways in healthy tissue. The body appears to handle exogenous sarcosine efficiently, clearing it from the blood within a few hours, as the pharmacokinetic data from the open-label study confirmed.

For people with schizophrenia or their family members exploring options, the practical reality is that sarcosine occupies an unusual space: it has more clinical trial evidence behind it than most supplements marketed for mental health, but far less than any approved medication. It is inexpensive and widely available, but unregulated. The trials show it helps some symptom domains when added to most antipsychotics, but not when added to clozapine. And the long-term safety profile, including any relationship to cancer risk, remains genuinely unknown. Anyone considering it should treat it as an experimental add-on therapy to discuss with their psychiatrist rather than a DIY treatment to start on their own.